Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to -$158.3 million.

  • Assembly Biosciences' Cash from Investing Activities fell 746.32% to -$158.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.4 million, marking a year-over-year decrease of 230.44%. This contributed to the annual value of $40.2 million for FY2024, which is 158.10% up from last year.
  • Assembly Biosciences' Cash from Investing Activities amounted to -$158.3 million in Q3 2025, which was down 1,031.33% from $17.0 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Cash from Investing Activities high stood at $33.0 million for Q1 2022, and its period low was -$158.3 million during Q3 2025.
  • For the 3-year period, Assembly Biosciences' Cash from Investing Activities averaged around -$14.9 million, with its median value being $6.6 million (2025).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 410.88% in 2022, then tumbled by 746.32% in 2025.
  • Quarterly analysis of 5 years shows Assembly Biosciences' Cash from Investing Activities stood at -$8.5 million in 2021, then surged by 295.21% to $16.6 million in 2022, then crashed by 641.32% to -$89.7 million in 2023, then surged by 92.53% to -$6.7 million in 2024, then crashed by 746.32% to -$158.3 million in 2025.
  • Its Cash from Investing Activities stands at -$158.3 million for Q3 2025, versus $17.0 million for Q2 2025 and $6.6 million for Q1 2025.